Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
On March 3, AMCP responded to a Request for Information from the Healthy Futures Subcommittee on Modernization, supporting legislative and regulatory solutions to remove barriers to coverage and payment for Digital Therapeutics in the Medicare program.
On Feb. 9, AMCP submitted comments to CMS supporting the agency's proposal to cover anti-amyloid monoclonal antibodies through the Coverage with Evidence Development pathway.
On Feb. 14, AMCP joined a pharmacy stakeholder letter supporting Dr. Robert Califf's nomination for FDA Commissioner, a post he previously held in 2016.
On Dec. 28, CMS released a proposed rule that would, in part, propose that adverse tiering is presumptively discriminatory and require that QHP issues offer more standardized plan options.
On Jan. 6, CMS released a proposed rule that would require pharmacy price concessions be passed to patients at the point-of-sale and reinstate detailed MLR reporting requirements.
On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.
AMCP joins other organizations in a letter of support for Dr. Robert Califf's nomination for FDA Commissioner.
On December 8, AMCP sent a letter of support to the Senate for Dr. Robert Califf's nomination to be FDA Commissioner.
AMCP joined other organizations to call on the business community to support the new federal requirement that those working for companies with more than 100 employees be vaccinated for COVID.
On Oct. 28, AMCP joined a pharmacy stakeholder coalition letter to HHS requesting authorizations for pharmacists, pharmacy technicians and interns to order and administer antiviral medications and flu tests.
On Nov. 2, AMCP joined a pharmacy stakeholder coalition letter to CMS requesting the agency use its PREP Act authority to establish payment mechanisms for Medicare and Medicaid to reimburse pharmacists for COVID-19 patient assessment services.
In October, AMCP joined other pharmacy organizations in supporting the Pharmacist's Fundamental Responsibilities and Rights released by APhA and the National Alliance of State Pharmacy Associations (NASPA). These principles focus on pharmacists' responsibilities and the workplace conditions necessary to fulfill those responsibilities.
